Letter from the Editor
Letter from the Editor
Over 14,000 attendees from around the world attended the 71st AAN Annual Meeting in Philadelphia. With 3,000+ presented abstracts, every aspect of brain research has its place at the conference, meaning every neurologist can find their topic of interest.
Dear Reader, Over 14,000 attendees from around the world attended the 71st AAN Annual Meeting in Philadelphia. With 3,000+ presented abstracts, every aspect of brain research has its place at the conference, meaning every neurologist can find their topic of interest.
Progress in common disorders such as dementia, epilepsy, migraine, and multiple sclerosis and advances in oligonucleotide approaches to rare diseases While research successfully continues in major fields of dementia, epilepsy, migraine, and multiple sclerosis, this year’s AAN was one of emerging science in more rare disorders. Very positive results were reported for three phase 3 trials using three different monoclonal antibodies in NMOSD, which might result in the first approved therapies. Progress has also been made regarding treatment options in rare neuromuscular disorders, such as myasthenia gravis, Charcot-Marie-Tooth, and spinal muscular atrophy. Clearly the search for effective treatments in all fields of neurology needs to continue. The same holds for improved diagnosis and disease management, with an ever-increasing role for digital technologies.
This report includes summaries of these presentations and more. We hope to provide an interesting read for those who were unable to attend, or would like to recap their experience at a busy conference.
Best regards, Hans-Peter Hartung
Prof. Hartung has been Chair of the Department of Neurology at Heinrich-Heine-University in Düsseldorf since 2001. He is also Director of the Center of Neuropsychiatry and the Department of Conservative Medicine at Univer-sity Hospital Düsseldorf. He studied medicine at the Universities of Düsseldorf, Glasgow, Oxford, and London. After graduation he served an immunology fellowship at the University of Mainz. Prof. Hartung’s clinical and translational research interests are in the field of basic and clinical neuroimmunology and in particular multiple sclerosis and immune neuropathies. He has been involved as steering committee mem-ber in multiple clinical trials of new drugs for the treatment of multiple scle-rosis, Guillain-Barre syndrome, and chronic inflammatory demyelinating pol-yneuropathy. Prof. Hartung is a former President of ECTRIMS.
Disclosures: Hans-Peter Hartung has received fees for consulting, speaking, and serving on steering committees from Bayer Healthcare, Biogen, GeNeuro, MedIm-mune, Merck, Novartis, Opexa, Receptos Celgene, Roche, Sanofi Genzyme, CSL Behring, Octapharma, and Teva, with approval by the Rector of Hein-rich-Heine-University.
Article image: Medicom
The content and interpretation of these conference highlights are the views and comments of the speakers/authors.